On April 16, 2009, Pharmacyclics, Inc. a Delaware corporation (the "Registrant"), announced an update to its clinical programs targeting histone deacetylase (HDAC) with its drug candidate PCI-24781 that is currently in multiple clinical trials for treating various solid and hematologic tumors. In addition, the Company announced multiple presentations regarding its orally available HDAC inhibitor compound at the annual AACR meeting in Denver, Colorado.

The foregoing description is qualified in its entirety by reference to the Registrant's Press Release dated April 16, 2009, a copy of which is attached hereto as Exhibit 99.1 and incorporated herein by reference.

(d) Exhibits.

                    Exhibit No.    Description
                       99.1        Press Release of Pharmacyclics, Inc. dated April 16, 2009.


--------------------------------------------------------------------------------
--------------------------------------------------------------------------------